EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers-Reference-Cited by-同舟云学术

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Published:2020-07-24 Issue:12 Volume:75 Page:3287-3289
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Bakker Daphne S.¹²^ORCID,Ariens Lieneke F. M.¹^ORCID,Giovannone Barbara²,Hijnen DirkJan³^ORCID,Delemarre Eveline M.²⁴,Knol Edward²,Nierkens Stefan²⁴,Bruin‐Weller Marjolein S.¹^ORCID,Thijs Judith L.¹²^ORCID,Drylewicz Julia²^ORCID

Affiliation:

1. Department of Dermatology and Allergology University Medical Center Utrecht Utrecht The Netherlands

2. Center for Translational Immunology Utrecht The Netherlands

3. Department of Dermatology Erasmus Medical Center Rotterdam The Netherlands

4. Platform Immune Monitoring (PIM) University Medical Center Utrecht Utrecht The Netherlands

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14492

Reference10 articles.

1. Atopic Dermatitis Diagnostic Criteria and Outcome Measures for Clinical Trials: Still a Mess

2. Biomarkers for atopic dermatitis

3. EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

4. Atopic dermatitis: correlation of peripheral blood T cell activation, eosinophilia and serum factors with clinical severity

5. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration;Allergy;2024-08-04

2. Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review;eBioMedicine;2024-05

3. Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis;Life;2024-03-07

4. Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation;Clinical & Experimental Allergy;2023-12-30

5. Prediction of disease severity using serum biomarkers in patients with mild-moderate Atopic Dermatitis: A pilot study;PLOS ONE;2023-11-02